Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238996 | 0.92 | SLC6A2 (0.39) | KEAP1SMN1; SMN2KDM4EALDH1A1USP2 | |
| SCHEMBL9085403 | 0.90 | SLC6A2 (0.38) | KEAP1SMN1; SMN2KDM4EALDH1A1SLC6A2 | |
| SCHEMBL4526655 | 0.88 | KEAP1 (0.48) | KEAP1SMN1; SMN2KDM4EALDH1A1USP2 | |
| SCHEMBL5419103 | 0.81 | KEAP1 (0.41) | KEAP1SMN1; SMN2KDM4EALDH1A1SLC6A2 | |
| SCHEMBL11883477 | 0.78 | USP2 (0.52) | KEAP1SMN1; SMN2KDM4EALDH1A1USP2 | |
| SCHEMBL231163 | 0.77 | KMT2A (0.37) | SMN1; SMN2ALDH1A1USP2HPGDTSHR | |
| SCHEMBL27586544 | 0.77 | ALDH1A1 (0.39) | KDM4EALDH1A1USP2HPGDPOLB | |
| SCHEMBL17393052 | 0.77 | ALDH1A1 (0.43) | KEAP1SMN1; SMN2KDM4EALDH1A1USP2 | |
| SCHEMBL646006 | 0.76 | KEAP1 (0.39) | KEAP1SMN1; SMN2KDM4EALDH1A1USP2 | |
| SCHEMBL11708888 | 0.75 | USP2 (0.48) | KEAP1SMN1; SMN2KDM4EALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892534-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2892534-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| WO-2014039714-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | KIT, PRKCH, PRKACA | KEAP1 2938/4885SMN1; SMN2 2565/4885KDM4E 1125/4885 |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | KEAP1 2938/4885SMN1; SMN2 2565/4885KDM4E 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.